

Mirataz

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued / amended on	Product Information affected ²	Summary ³
IB/0003/G	This was an application for a group of variations. B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	15/01/2021		SPC, Annex II, Labelling and PL	The Agency accepted the group of variations to introduce an alternative secondary packaging, to change the batch release site and implement minor changes to test procedures.
IB/0002	C.II.7.b - Introduction of a new Pharmacovigilance system - Which has been assessed by the relevant national competent authority/EMA for another product of the same MAH	27/06/2020	n/a		n/a

¹ Notifications are issued for type I variations (unless part of a group including a type II variation or higher procedure or a worksharing application). Opinions are issued for all other procedures.



² SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

³ Since October 2019 summary information is no longer published for variations that do not impact upon the product information

T/0001	Transfer of Marketing Authorisation	11/05/2020	24/06/2020	SPC, Labelling and PL	The European Commission transferred the marketing authorisation from "Aniserve GmbH" to "Dechra Regulatory B.V."